Lung cancer
Conditions
Interventions
Patients receive 4 courses of CBDCA/S-1. Chemotherapy with S-1 is continued for patients who do not have PD
Sponsors
Hamamatsu University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically or pathologically proven lung squamous cell carcinoma 2) Locally advanced or metastatic, recurrent non-small cell lung cancer 3) Age more than 20 years 4) Performance status (ECOG) of 0-1 5) Life expectancy of more than 3 months 6) Patients with ability of oral intake 7) Patients who has at least one or more measurable lesion by RECIST 8) Patients who have adequate organ function 9) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Patients who received previous treatment with the 5-FU 2) Patients who is contraindicated to administration of CBDCA and S-1 3) Patients with a history of the drug hypersensitivity 4) Patients with symptomatic metastases to brain 5) Uncontrolled massive pleural effusion, ascitic fluid and pericardial fluid retention case 6) Patients with watery diarrhea 7) Patients with serious complications 8) Patients with active concomitant malignancy 9) Patients with HBs antigen-positive or with HCV antibody-positive 10) Patients who uses flucytosine 11) Women with the pregnant possibility, a pregnancy or lactation and men with willing to get pregnant 12) Patients who were complicated with mental disease or neurologic manifestation, and it is judged that the participation in study is difficult 13) Any other cases who are regarded as inadequate for study enrollment by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, 1-year survival Rate, Response Rate, Safety | — |
Countries
Japan
Contacts
Public ContactYasuhiro Ito
Hamamatsu University School of Medicine The Second Division, Department of Internal Medicine
Outcome results
None listed